Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

Reem Karmali, MDMSc, Jeremy S Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M Petrich, MD, Ephraim Hochberg, MD, Ronald Takvorian, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137695

Published: 2020

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, Haesook T. Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Caron A. Jacobson, MD, Ephraim Hochberg, MD, Ronald Takvorian, MD, Jeremy S. Abramson, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2016) 128 (22): 3243.

https://doi.org/10.1182/blood.V128.22.3243.3243

Published: 2016

Journal Articles

Statin Use Improves Overall Survival and Time to Treatment Failure in Patients with Primary CNS Lymphoma.

Lauren Ciminello, Christiana Toomey, Julien Cobert, Fred H Hochberg, MD, Jeremy S. Abramson, MD, Ephraim Hochberg, MD

Blood (2009) 114 (22): 2496.

https://doi.org/10.1182/blood.V114.22.2496.2496

Published: 2009

Journal Articles

Automated Analysis and Codification of Free Text Pathology Reports

Bill Long, Aliyah Rahemtullah, MD, Christiana E. Toomey, Adam Ackerman, Jeremy S. Abramson, MD, Ephraim Hochberg, MD

Blood (2008) 112 (11): 2394.

https://doi.org/10.1182/blood.V112.11.2394.2394

Published: 2008

Journal Articles

High False Positive Rate with the Use of CT and FDG-PET in Post-Remission Surveillance for Hodgkin Lymphoma.

Dan Zuckerman, MD, Ann Lacasce, MD, Eric Jacobsen, MD, Tak Takvorian, MD, Ephraim Hochberg, MD

Blood (2007) 110 (11): 2327.

https://doi.org/10.1182/blood.V110.11.2327.2327

Published: 2007

NARROW

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Statin Use Improves Overall Survival and Time to Treatment Failure in Patients with Primary CNS Lymphoma.

Automated Analysis and Codification of Free Text Pathology Reports

High False Positive Rate with the Use of CT and FDG-PET in Post-Remission Surveillance for Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Statin Use Improves Overall Survival and Time to Treatment Failure in Patients with Primary CNS Lymphoma.

Automated Analysis and Codification of Free Text Pathology Reports

High False Positive Rate with the Use of CT and FDG-PET in Post-Remission Surveillance for Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only